MAPT and amyloidosis: In this framework, “A” biomarkers refer to amyloidosis [abnormal tracer retention on amyloid positron emission tomography (PET) imaging and low β-amyloid (Aβ) concentration in the cerebrospinal fluid (CSF)]; “T” biomarkers, the value of increased CSF phosphorylated tau (P-tau) and cortical tau PET; and “N,” biomarkers of neurodegeneration or neural injury [higher CSF total tau (T-tau), diminished 18F-fluorodeoxyglucose (FDG)-PET and atrophic brain structures in magnetic resonance image (MRI)] [1].